Northwestern University Feinberg School of Medicine

Department of Dermatology

Clinical Trials

Clinical and Outcomes Research under the direction of the Department of Dermatology is conducted at the Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, and Northwestern Lake Forest Hospital dermatology clinics.

For more information about the research or participation, please call our office at 312-503-5944.

Trials
Tissue repository
Northwestern University’s Department of Dermatology is collecting skin, hair, nail, blood, saliva, skin and/or buccal swabs, and mucous membrane(part of your skin which lines body passages and cavities such as the inside of your mouth or nose), and other tissue samples for use …
Northwestern University’s Department of Dermatology is collecting skin, hair, nail, blood, saliva, skin and/or buccal swabs, and mucous membrane(part of your skin which lines body passages and cavities such as the inside of your mouth or nose), and other tissue samples for use in a biorepository. By operating this biorepository, the Department of Dermatology hopes to develop a better understanding of skin diseases (meaning the knowledge about how cells in the skin behave and react to medical treatments) among researchers at Northwestern University and other approved researchers. This basic knowledge is expected to help the development of more effective patient care and new treatment methods.
-Having specimens collected as part of a standard of care procedure;
-Have a skin disease which researchers want samples of in order to further understand
it; or
-Qualify as a healthy volunteer whose samples researchers can use as control samples
for research.
Rangel, Stephanie MarieRangel, Stephanie Marie
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00009443
More Info

For more information on this study please contact us:

Belback, Madeleine
D1447 - SGX301
To evaluate the safety and effectiveness of the topical ointment (cream), SGX301, in combination with light therapy in patients with cutaneous T-cell lymphoma.
Must be 18 years of age or older, with a clinical diagnosis of Cutaneous T- Cell Lymphoma, Myucosis Fungoides, Stage IA. Stage IB, or Stage IIA, and willing to refrain from sunbathing for duration of the study.
Guitart, JoanGuitart, Joan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02448381 STU00200530
More Info

For more information on this study please contact us:

Bagnowski, Katherine
D1465 - Asthma and AD PROMIS (PEPR)
The purpose of this study is to validate a specific itch tool and its relation to skin disease severity in children ages 5-17 who have symptoms of itch (ie, primary dermatologic conditions: atopic dermatitis, epidermolysis bullosa, ichthyosis, psoriasis, etc; or ot…
The purpose of this study is to validate a specific itch tool and its relation to skin disease severity in children ages 5-17 who have symptoms of itch (ie, primary dermatologic conditions: atopic dermatitis, epidermolysis bullosa, ichthyosis, psoriasis, etc; or other conditions that result in itch such as cancer and pruritic responses to therapy, chronic liver or renal diseases, patients who receive cancer therapy) The study will look at how well Patient Reported Outcomes Measurement Information System (PROMIS) tools uncover meaningful changes in disease status as well as build a list of items relating to pediatric skin diseases and a PRO model for signs and symptoms of skin disease. Surveys can be done remotely.
Paller, AmyPaller, Amy
  • Map it 676 N. St. Clair St.
    Chicago, IL
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00202292
More Info

For more information on this study please contact us:

Ramachandran, Divya
(CIRB) - Paller - (Ichthyosis)
Ichthyosis is a group of genetic skin disorders that present with dry, thickened, scaly, or flaky skin. As of today, there is no cure or treatment. Doctors can only treat the dry skin with different types of emollients to soften the scale. A deeper understanding of this…
Ichthyosis is a group of genetic skin disorders that present with dry, thickened, scaly, or flaky skin. As of today, there is no cure or treatment. Doctors can only treat the dry skin with different types of emollients to soften the scale. A deeper understanding of this disease is required to develop better treatments. There are different types of cells and cell-produced signals (biomarkers) that are being studied in order to help find these new treatments. Looking at biomarkers has been successful in helping us to understand other skin disorders better. The purpose of this study is to determine which blood and skin biomarkers characterize ichthyosis in children.
Subjects (1 year to 60 years of age) with Autosomal Recessive Congenital Ichthyosis (ARCI), which includes lamellar Ichthyosis, Netherton Syndrome, or other ichthyosis subtypes will be enrolled.
Healthy control subjects will be enrolled for either a blood sample or skin sample, and/or tape strip samples.
Paller, AmyPaller, Amy
  • Map it 676 N. St. Clair St.
    Chicago, IL
  • Map it 225 E. Chicago Ave.
    Chicago, IL
  • Map it 1131 Techny Rd.
    Northbrook, IL
STU00203051
More Info

For more information on this study please contact us:

Canter, Talia
(CIRB) L1019 Paller - ASP093015 (Harlequin Ichthyosis)
The goal of this study is to understand the pattern of joint pain and what pain management options or treatments have worked for individuals with joint disease related to Harlequin Ichthyosis (HI). Participation in the study will involve complet…
The goal of this study is to understand the pattern of joint pain and what pain management options or treatments have worked for individuals with joint disease related to Harlequin Ichthyosis (HI). Participation in the study will involve completing a one-time survey administered through letter mailing, emailing, link using an online survey, or in person at the Lurie Children’s Dermatology Clinic. The survey will take about 15-30 minutes.
Confirmed diagnosis of Harlequin Ichthyosis (HI) and have complaints of joint pain, difficulty walking, swelling or other similar issues with your muscles and bones.
Paller, AmyPaller, Amy
  • Map it 676 N. St. Clair St.
    Chicago, IL
  • Map it 225 E. Chicago Ave.
    Chicago, IL
  • Map it 1131 Techny Rd.
    Northbrook, IL
STU00203185
More Info

For more information on this study please contact us:

Singh, Prableen
(CIRB) Paller - (AD Biomarkers)
Atopic dermatitis (AD), also called eczema, is a disease in which the skin is dry and scaly with severe itching that may continue despite treatment. A deeper understanding of this disease is required to develop new and better treatments. There are different types of ce…
Atopic dermatitis (AD), also called eczema, is a disease in which the skin is dry and scaly with severe itching that may continue despite treatment. A deeper understanding of this disease is required to develop new and better treatments. There are different types of cells and cell-produced signals (biomarkers) that have been found in adults with AD. Nevertheless, there may be significant differences between AD in children versus adults. The purpose of this study is to determine which blood and skin biomarkers characterize AD in children by looking at the blood and skin biomarkers of children with AD and children without AD.
This study will enroll children ages 0 months to 17 years to collect blood, skin, saliva and tape strip samples in order to look at biomarkers related to AD. Children who have or have not been diagnosed with AD or an atopic condition, such as allergies or asthma.
Paller, AmyPaller, Amy
  • Map it 676 N. St. Clair St.
    Chicago, IL
  • Map it 225 E. Chicago Ave.
    Chicago, IL
  • Map it 1131 Techny Rd.
    Northbrook, IL
STU00203272
More Info

For more information on this study please contact us:

Canter, Talia
D1481 Guitart - Elorac EL-1007-01-01 (Naloxone)
The main goal of this study is to test the efficacy and safety of topical Naloxone for itching in patients with MF.
21 years of age or older with a diagnosis of mycosis fungoides (MF) with itching present on a daily basis for more than one month and willing to fill out a diary for 7 days to provide severity of itch before enrollment.
Guitart, JoanGuitart, Joan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02811783 STU00203078
More Info

For more information on this study please contact us:

Bagnowski, Katherine
D1489 Choi (Topical Steroids for EGFRI PE)
EGFR inhibitors are biologic agents used to treat certain cancers including non-small cell lung, colorectal, head and neck, and pancreatic carcinomas. These agents often have a side effect of an acne like rash that in some cases can be quite severe. This ras…
EGFR inhibitors are biologic agents used to treat certain cancers including non-small cell lung, colorectal, head and neck, and pancreatic carcinomas. These agents often have a side effect of an acne like rash that in some cases can be quite severe. This rash has been shown to be inflammatory in origin but is currently treated with antibiotics if it appears. The main goal of this study is to test if patients treated with steroid cream, (added) which is an anti-inflammatory medication, (added) before a rash develops have a less severe rash than patients who do not use a steroid cream before a rash develops.
Must be 18 years of age or older with a diagnosis of cancer and starting an (changed from 'and') EGFR inhibitor. During the study you must be willing to fill out a daily diary, use sunscreen and cream daily, and fill out 2 questionnaires and have photographs taken every 2 weeks for 4 visits.
Choi, JenniferChoi, Jennifer
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03115567 STU00203631
More Info

For more information on this study please contact us:

Erickson, Maia
D1460 Amin - Corrona-PSO-500 Psoriasis Registry
The main purpose of the Corrona Psoriasis registry is to learn more about psoriasis, how doctors treat psoriasis, how well medications and treatments work, and the safety of those treatments.
To be eligible, you need to be 18 years of age or older, have been diagnosed with psoriasis by a dermatologist, and have started on or switched to a systemic biologic psoriasis treatment within the previous 12 months by a Northwestern dermatologist.
Amin, AhmadAmin, Ahmad
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00203552
More Info
psoriasis

For more information on this study please contact us:

Paiva Costa TeixeiraFigueiredo, Anna Carolina
D1491 Kundu - Regeneron (Keloid)
Northwestern’s Department of Dermatology is performing a research study to better understand the causes of keloid scars. Keloid scars are solid tissue overgrowths that tend to develop after trauma to the skin.
Subjects who are 18 years of age or older. Have no history of keloids or have a keloid on the earlobe or on another area of your body that either has not been treated or if treated, the treatment took place more than 6 months ago.
Kundu, Roopal VashiKundu, Roopal Vashi
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03228693 STU00203462
More Info
keloid

For more information on this study please contact us:

Ali, Yasmeen
18-052 Le Poole (Microbiome in Vitiligo)
Volunteers are needed for a study on the microbiome of subjects with and without vitiligo. For patients with vitiligo and without vitiligo, the study will include an initial visit, at which time swab or tape strip samples of the skin and swab samples of…

Volunteers are needed for a study on the microbiome of subjects with and without vitiligo. For patients with vitiligo and without vitiligo, the study will include an initial visit, at which time swab or tape strip samples of the skin and swab samples of stool will be collected. All subjects will be asked to complete questionnaires about their skin care regimen and dietary habits. Subjects with vitiligo will be required to follow up for additional specimen collection and questionnaire completion after six months and one year.

Volunteers over the age of 18 are eligible to participate. Study is recruiting those with and without vitiligo. 
Le Poole, IsabelleLe Poole, Isabelle
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00206844
More Info

For more information on this study please contact us:

Belback, Madeleine
(xIRB) 18-063 Paller (The Big Study)
The purpose of this study is to understand the possible burden of skin disorders in school-age children, such as its impact on the development of anxiety, depression and relationships with friends. The study will look at the relationship between the burden …

The purpose of this study is to understand the possible burden of skin disorders in school-age children, such as its impact on the development of anxiety, depression and relationships with friends. The study will look at the relationship between the burden and how severe or visible the skin problem is.​ Surveys can be done remotely.

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00207281
More Info

For more information on this study please contact us:

Canter, Talia
(xIRB) 18-176 Paller - Pediatric Psoriasis Lipoproteins
Psoriasis is a skin condition that causes red, scaly, itchy patches on the skin. Psoriasis is associated with inflammation that may play a role in heart disease, stroke, diabetes, obesity and other metabolic disease. Lipoproteins (substan…

Psoriasis is a skin condition that causes red, scaly, itchy patches on the skin. Psoriasis is associated with inflammation that may play a role in heart disease, stroke, diabetes, obesity and other metabolic disease. Lipoproteins (substances made up of fat and protein), cholesterol, and other proteins associated with inflammation have specifically been shown to be abnormal in psoriasis patients. The purpose of this study is to investigate if systemic psoriasis medication changes the makeup of these inflammatory substances and lipoproteins in the blood. If systemic therapy is shown to improve levels of these substances in the blood,it may indicate prevention against the development of heart disease, stroke,diabetes, obesity and other metabolic disease. Subjects will be required to have one fasting blood draw for collection of research samples. 

Ages 6 to 17 years and havepsoriasis, acne, or are healthy volunteers. Participants with psoriasis musthave a 6 month or more history of treatment with a topical medication or have a3 month or less history of treatment with a systemic (works throughout thewhole body) medication. Participants with acne must currently be treated with amedication called isotretinoin. Participants who are healthy volunteers areasked to participate because they have the same body composition as anotherparticipant in this study with psoriasis or acne. 

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00208518
More Info

For more information on this study please contact us:

Singh, Prableen
(xIRB) 18-163 Paller (Genetic Analysis of Pediatric Psoriasis)
Psoriasis is a skin condition that causes red, scaly, itchy patches. There is a gene called CARD14 and some mutations in CARD14 cause psoriasis in both children and adults. These mutations can be passed down from parents to …

Psoriasis is a skin condition that causes red, scaly, itchy patches. There is a gene called CARD14 and some mutations in CARD14 cause psoriasis in both children and adults. These mutations can be passed down from parents to children in families, but a child with no family history of psoriasis could also have a new mutation in CARD14 that causes psoriasis.

The purpose of this study is to see what kinds of mutations in the CARD14 gene cause psoriasis and what new mutations in other genes can cause psoriasis in a child with no family history of psoriasis. Participants will be assessed for demographics, clinical, medication, and family history as well as severity of psoriasis at the study visit (in-clinic or over the phone). Saliva samples or buccal swabs will be obtained from all subjects.

Patients of any age who developedpsoriasis before 12 years of age and who have no family history of psoriasis ineither parent, parents of patients who developed psoriasis before 12 years ofage, and up to third-degree family members (first cousin, grandparent,great-grandparent) with or without psoriasis if family history is indicated.All participants must be able to give a saliva or buccal swab sample. 

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00208556
More Info

For more information on this study please contact us:

Singh, Prableen
(xIRB) 18-127 Kruse - LEO LP0162-1334
This is a clinical research study to test if the study drug, tralokinumab, is better than a placebo at treating moderate to severe atopic dermatitis. In this study participants will either get the study drug, tralokinumab or a placebo. The effectivene…

This is a clinical research study to test if the study drug, tralokinumab, is better than a placebo at treating moderate to severe atopic dermatitis. In this study participants will either get the study drug, tralokinumab or a placebo. The effectiveness and safety of tralokinumab will be judged by a range of assessments that rate the severity and extent of atopic dermatitis,itch and several other symptoms, as well as general health status and quality of life.

Ages 12 to 17 years with a diagnosis of atopic dermatitis for at least 1 year, with moderate to severe atopic dermatitis at screening and baseline visit, and have had history of topical corticosteroid and/or topical calcineurin inhibitor treatment failure or are medically inadvisable for use of these topical atopic dermatitis treatments. 

Kruse, LaceyKruse, Lacey
  • Map it 225 E. Chicago Ave.
    Chicago, IL
NCT03526861 STU00208583
More Info

For more information on this study please contact us:

Singh, Prableen
(xIRB) 19-002 Paller - Wool Clothing for AD
This is a clinical research study that aims to determine if there is an improvement in eczema in children when they wear superfine merino wool clothing. Participants will be randomly assigned to two groups and begin with wool garments for 6 weeks and switch…
This is a clinical research study that aims to determine if there is an improvement in eczema in children when they wear superfine merino wool clothing. Participants will be randomly assigned to two groups and begin with wool garments for 6 weeks and switch to standard garments for 6 weeks or begin with standard garments for 6 weeks and switch to wool garments for a further 6 weeks. Participants will attend follow-up appointments at 3, 6, 9 and 12 weeks where severity of eczema,quality of life, and any side effects will be assessed. Wool clothing and laundry detergent will be provided for the duration of the entire study. 

Ages 3 months to 5 years with moderate to severe eczema as determined atinitial visit.

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00208730
More Info

For more information on this study please contact us:

Ramachandran, Divya
18-145 Paller AbbVie M16-045
MeasureUp 1 is a clinical research study that will test if the study drug “upadacitinib”is better than placebo at treating moderate to severe atopic dermatitis. Inthis study, you will either get the study drug (upadacitinib) or a placebo. Theeffectiveness and safety o…
MeasureUp 1 is a clinical research study that will test if the study drug “upadacitinib”is better than placebo at treating moderate to severe atopic dermatitis. Inthis study, you will either get the study drug (upadacitinib) or a placebo. Theeffectiveness and safety of upadacitinib will be judged by a range ofassessments that rate the severity and extent of atopic dermatitis, itch andseveral other symptoms, as well as general health status and quality of life.
Ages12 to 75 with symptoms of moderate to severe atopic dermatitis for at least 3years, and have had inadequate response to treatment with topical medication orhave been taking systemic treatments in the last 6 months. 
Paller, AmyPaller, Amy
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03569293 STU00207913
More Info

For more information on this study please contact us:

Onate, Alejandra
(xIRB) 19-006 Kruse - Sanofi OBS15333 (PEDISTAD)
PEDISTAD is an observational study to assess the features of children with moderate to severe atopic dermatitis, also called eczema,whose disease is not adequately controlled with topical therapies (creams orlotions) or when those therap…

PEDISTAD is an observational study to assess the features of children with moderate to severe atopic dermatitis, also called eczema,whose disease is not adequately controlled with topical therapies (creams orlotions) or when those therapies are not medically advisable.

Participants in this non-interventional study will be treated in the usual way for their conditions and will not undergo extra tests. The study will document how atopic dermatitis and other diseases linked to atopic dermatitis changes over time and will also investigate the influence of routine clinical practice on clinical results to understand how atopic dermatitis affects children and their caregivers in their daily lives. There is an optional, additional study that will also enroll subjects for the collection of research specimens during regularly scheduled clinic appointments for biomarker analysis. 

Ages <12 years old with moderate to severe atopic dermatitiswho are currently receiving systemic treatment (including phototherapy) foratopic dermatitis, or currently on topical treatment but otherwise candidatesfor systemic treatment for either lack of adequate control and/or safetyconcerns with long-term topical treatment. 

Kruse, LaceyKruse, Lacey
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00209263
More Info

For more information on this study please contact us:

Singh, Prableen
XIRB-Light Treatment Effectiveness (LITE) Study
The purpose of this study is to compare the effectiveness, safety (tolerability), and duration of treatment response at 12 weeks of home versus office-based narrowband UVB phototherapy for the treatment of psoriasis. Phototherapy delivered at hom…

The purpose of this study is to compare the effectiveness, safety (tolerability), and duration of treatment response at 12 weeks of home versus office-based narrowband UVB phototherapy for the treatment of psoriasis. Phototherapy delivered at home or the office are both common treatments for psoriasis but it is not known how well they compare to one another.

12 years or older with plaque or guttate psoriasis predominantly on trunk and/or extremities. Patient needs to be willing to comply with in-office or in-home phototherapy.  
Amin, AhmadAmin, Ahmad
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00209270
More Info

For more information on this study please contact us:

Paiva Costa TeixeiraFigueiredo, Anna Carolina
17-188 Choi (PCIA)
This study will test if low-dose oral minoxidil has aneffect on permanent chemotherapy-induced alopecia (defined as hair loss afterthe completion of a chemotherapy regimen that persists for over six months). Inthis study, you will receive the study drug; there is no placebo …

This study will test if low-dose oral minoxidil has aneffect on permanent chemotherapy-induced alopecia (defined as hair loss afterthe completion of a chemotherapy regimen that persists for over six months). Inthis study, you will receive the study drug; there is no placebo option. Theeffectiveness and safety of the treatment will be determined by a range of assessments,including biopsies, images, and subjective evaluation of perceived hair growth.

Age 18 and above with a diagnosis of permanentchemotherapy-induced alopecia and agree to use contraception for the durationof the study.

Choi, JenniferChoi, Jennifer
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03831334 STU00206882
More Info

For more information on this study please contact us:

Erickson, Maia
18-142 Paller - AbbVie M16-047
ADUp is a clinical research study that will test if the study drug “upadacitinib”in combination with topical corticosteroids (TCS) is better than placebo incombination with TCS at treating moderate to severe atopic dermatitis. In thisstudy, you will either get the s…
ADUp is a clinical research study that will test if the study drug “upadacitinib”in combination with topical corticosteroids (TCS) is better than placebo incombination with TCS at treating moderate to severe atopic dermatitis. In thisstudy, you will either get the study drug (upadacitinib) with TCS or a placebowith TCS. The effectiveness and safety of upadacitinib will be judged by arange of assessments that rate the severity and extent of atopic dermatitis,itch and several other symptoms, as well as general health status and qualityof life.
Ages12 to 75 with a diagnosis of moderate to severe atopic dermatitis for at least 3years, and have had inadequate responses or intolerance to treatment withtopical medication within 6 months prior to the baseline visit. 
Paller, AmyPaller, Amy
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03568318 STU00207896
More Info

For more information on this study please contact us:

Onate, Alejandra
(xIRB) 19-016 Paller - Lenus, RGN-137-EB-202
Epidermolysis bullosa(EB) is a group of genetic conditions that cause blistering of the skin. In the Junctional EB (JEB) and Dystrophic EB (DEB) subtypes, EB wounds do not heal easily and can result in permanent and disfiguring scarring. The ex…

Epidermolysis bullosa(EB) is a group of genetic conditions that cause blistering of the skin. In the Junctional EB (JEB) and Dystrophic EB (DEB) subtypes, EB wounds do not heal easily and can result in permanent and disfiguring scarring. The experimental drug in this study, a Tβ4 topical gel, is being tested in these two subtypes because of Tβ4’s wound healing characteristics. The study will compare how well 0.03% RGN-137 (Tβ4 topical gel)works and how safe it is compared to a placebo gel (which looks like the study drug but does not have any active drug ingredient) in the treatment of JEB or DEB.

Males or females who are at least 4 years old with adiagnosis of Junctional EB (JEB) or Dystrophic EB (DEB).

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
NCT03578029 STU00209415
More Info

For more information on this study please contact us:

Singh, Prableen
18-167 Colavincenzo - Eli Lilly I4V-MC-JAHO (BRAVE-AA1)
Alopecia Areata is much more than losing your hair. It’s an autoimmune condition that can cause severe emotional distress, including depression and anxiety  - and can get in the way of living a full life. There are no FDA…

Alopecia Areata is much more than losing your hair. It’s an autoimmune condition that can cause severe emotional distress, including depression and anxiety  - and can get in the way of living a full life. There are no FDA approved treatments for Alopecia Areata, but researchers are working hard to change that. A clinical research study is now underway throughout the country– and is seeking volunteers with Alopecia Areata affecting at least half of their scalp to participate. Qualified participants will receive study-related care and investigational medication at no cost to them. 

You mayqualify if you:

  • Are at least 18 years of age
  • Have experienced at least 50% of hair loss due to Alopecia Areata
Colavincenzo, Maria LColavincenzo, Maria L
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03570749 STU00208323
More Info

For more information on this study please contact us:

Paiva Costa TeixeiraFigueiredo, Anna Carolina
Choi DF/HCC,17-448
This is a clinical research study to test thesafety and effectiveness of the study drug, pembrolizumab, in treating patientswith anaggressive lymphoma or a histiocyte or dendritic cell neoplasm (tumor) that hasnot responded to or has come back after other treatments. The eff…

This is a clinical research study to test thesafety and effectiveness of the study drug, pembrolizumab, in treating patientswith anaggressive lymphoma or a histiocyte or dendritic cell neoplasm (tumor) that hasnot responded to or has come back after other treatments. The effectiveness andsafety of the treatment will be determined by a range of assessments includingbiopsies, scans (or imaging tests), as well as general health and performance status. 

Age 18 andabove with a diagnosis of a histiocyte/dendritic cell neoplasm orrelapsed/refractory aggressive lymphoma. Must be willing to provide tissue froma newly obtained biopsy, have normal organ and marrow function and not acandidate for potentially curative therapy at the time of enrollment.

Choi, JaehyukChoi, Jaehyuk
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03316573 STU00209675
More Info
lymphoma

For more information on this study please contact us:

Bagnowski, Katherine